Valencia Technologies Secures $35 Million Investment for UUI Device

News Summary

Valencia Technologies has announced a $35 million investment to expand its neuromodulation efforts for urgency urinary incontinence (UUI). The funding, provided by Brooks Advisory Group, aims to accelerate the commercialization of the eCoin® system, a minimally invasive treatment for UUI. New CEO James D. Surek will lead the initiative, and the company has garnered FDA approval for the eCoin system. Medical professionals commend the device as a promising alternative to traditional treatments, positioning Valencia Technologies for growth in the healthcare market.

Valencia, California – Valencia Technologies, a privately funded medical device company, has announced a significant investment of up to $35 million to propel its efforts in the neuromodulation sector, specifically targeting urgency urinary incontinence (UUI). The funding will be provided by Brooks Advisory Group, an affiliate of Brooks Management Group (BMG), and is primarily aimed at accelerating the commercialization of Valencia’s innovative product, the eCoin® system. This announcement comes at a time when demand for effective treatment options for UUI is on the rise.

To lead this growth initiative, Valencia Technologies has appointed James D. Surek as the new Chief Executive Officer. Surek brings a wealth of experience from the medical device industry, having demonstrated remarkable success in increasing revenues and facilitating corporate turnarounds at previous companies. His background will be crucial in steering Valencia Technologies as it seeks to broaden the reach of its groundbreaking solution.

The eCoin device is designed as a minimally invasive treatment option for individuals suffering from UUI. Recognized by the FDA, the eCoin is a coin-sized neurostimulator that is implanted just beneath the skin near the ankle in a straightforward outpatient procedure. Following the implantation, the device delivers periodic stimulation to the tibial nerve twice a week, which has been shown to reduce episodes of UUI by at least 50% in 75% of patients within one year of treatment. This level of efficacy provides a promising alternative for patients who may find conventional medications ineffective or who prefer to avoid more invasive surgical options.

Valencia Technologies received FDA approval for the eCoin system in 2022, marking it as the first and only FDA-approved subcutaneous implantable tibial nerve stimulator specifically for UUI. This innovative device not only offers an effective treatment pathway but also enhances the patient experience. Unlike traditional treatments requiring regular recharging and frequent follow-ups, the eCoin system simplifies post-implant procedures, necessitating minimal follow-up programming sessions.

Alongside the announcement of the investment and leadership changes, Brooks Advisory Group has committed to supporting Valencia Technologies in various operational aspects including commercialization, sales, reimbursement, and financial strategy development. This partnership is expected to bolster the company’s market position and ensure that more patients gain access to the eCoin system in a timely manner.

The leadership team at Valencia Technologies, now including Surek, has been reinforced with key players such as Dain Black and Ryan Brooks, who will collaborate with existing board members Jeff Greiner and Don Hubbard. Surek’s prior track record includes driving revenue growth exceeding $200 million in three years during his tenure at Advanced Bionics, eventually leading to the company’s acquisition by Boston Scientific for around $3 billion. Additionally, he successfully scaled revenue at Entellus Medical from under $1 million to more than $70 million within a four-year span and facilitated its IPO.

Medical professionals have expressed high regard for the eCoin system. For instance, Dr. Jason Kim from Stony Brook Medicine noted that the eCoin offers an effective alternative treatment compared to other medications and invasive procedures for patients grappling with overactive bladder issues. With recent advancements in technology and treatment methodologies, the eCoin device stands as a significant breakthrough in addressing one of the most pressing challenges faced by many individuals today.

This infusion of capital and strong leadership positions Valencia Technologies well for successful expansion, aiming to meet the unmet medical needs of patients suffering from urgency urinary incontinence while enhancing their quality of life through innovative treatment solutions.

Deeper Dive: News & Info About This Topic

• PR Newswire: Valencia Technologies Investment Announcement
• Wikipedia: Nerve Stimulation
• LA Business Journal: Avita FDA Approval
• Google Search: Urgency Urinary Incontinence
• Fortune: AI Integration in Healthcare
• Google Scholar: Medical Device Innovation
• LA Times: California News
• Encyclopedia Britannica: Neuromodulation
• Chicago Business: Who’s Who
• Google News: Medical Technology